

AUTHORS' REPLY

Singapore Med J 2019; 60(6): 323 <https://doi.org/10.11622/smedj.2019063>

Dear Sir,

We would like to thank the authors for taking note of our study.⁽¹⁾ As mentioned by Yasri and Wiwanitkit⁽²⁾ with regard to the viral factor, the Q80K mutation has been associated with use of direct-acting antivirals⁽³⁾ in the study by Ruggiero et al.⁽⁴⁾ Their treatment group included simeprevir, which is an NS3A inhibitor.

With regard to the use of other cytokines, an excellent study has been done by Sghaier et al.⁽⁵⁾ However, we did not do this variant testing, as our study was done much earlier. The use of IL28B polymorphism is mentioned as a "*viable treatment option*", and this has been studied in our group previously.⁽⁶⁾

Yours sincerely,

Benjy Yi-Min Soh^{1,2}, Rajneesh Kumar^{1,2}, Victoria Sze-Min Ekstrom^{1,2}, Clement Yi-Hao Lin¹, Sobhana D/O Thangaraju^{2,3}, Hwee Huang Tan⁴, Kwai Peng Chan^{2,5}, Lina Hui Lin Choong^{2,3}, Diana Teo⁴, Wan Cheng Chow^{1,2}

¹Department of Gastroenterology and Hepatology, Singapore General Hospital, ²Duke-NUS Medical School, ³Department of Renal Medicine, Singapore General Hospital, ⁴Health Sciences Authority, ⁵Department of Microbiology, Singapore General Hospital, Singapore. rajneeshkrs@gmail.com

REFERENCES

1. Soh BYM, Kumar R, Ekstrom VSM, et al. Prevalence of hepatitis C virus infection and the IL28B genotype polymorphism among blood donors and high-risk populations. *Singapore Med J* 2019;60:34-9.
2. Yasri S, Wiwanitkit V. Comment on: Prevalence of hepatitis C virus infection and the IL28B genotype polymorphism among blood donors and high-risk populations. *Singapore Med J* 2019; 60:323.
3. Shepherd SJ, Abdelrahman T, MacLean AR, et al. Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. *J Clin Virol* 2015; 65:50-3.
4. Ruggiero T, Proietti A, Boglione L, et al. Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience. *Arch Virol* 2015; 160:2881-5.
5. Sghaier I, Mouelhi L, Ghazoueni E, et al. Role of TLRs and IL-6 in the outcome of chronic hepatitis C treatment in Tunisian population. *Cytokine* 2017; 99:297-304.
6. Ekstrom V, Kumar R, Zhao Y, et al. Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable IL28B polymorphism. *Gastroenterol Rep (Oxf)* 2017; 5:208-12.